NCT00454298View on ClinicalTrials.gov

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Osteoarthritis
Interventions
DRUG

AGG-523 (Aggrecanase Inhibitor)

Trial Locations (5)

02120

Boston

02215

Boston

02462

Newton

01801

Winchester

01655

Worcester

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00454298 - Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement | Biotech Hunter | Biotech Hunter